Peficitinib: A New Hope for Rare Joint Tumors

Imagine a tough, benign tumor that grows in your joints and often comes back even after surgery. That's diffuse-type tenosynovial giant cell tumor (dTGCT) for you. Scientists are on a mission to find better drugs to treat this sneaky tumor. They've been looking at a signaling pathway called JAK/STAT, which plays a big role in a similar disease called rheumatoid arthritis. First, they collected cells from dTGCT patients and tested five drugs that are already used to treat rheumatoid arthritis. These drugs, called JAK inhibitors, block the JAK/STAT signaling pathway. Guess what? They found that this pathway is also very active in dTGCT.

Out of the five drugs, peficitinib came out on top. It was more effective than the others, including pexidartinib, which is the only drug approved by the FDA for dTGCT. Peficitinib works by blocking a specific protein called tyrosine kinase 2 (TYK2), which is crucial for the growth of dTGCT cells. So, not only did scientists find that the JAK/STAT pathway is key to understanding dTGCT, but they also discovered that peficitinib could be a game-changer in treating this tough tumor.

Actions